Inhibikase Therapeutics

IKT (NasdaqCM)

Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing treatments to modify the course of cardiopulmonary diseases, focused on pulmonary arterial hypertension (PAH). Its lead candidate, IKT-001, is an oral imatinib mesylate prodrug designed to reduce gastrointestinal side effects while preserving efficacy. Nonclinical safety and healthy-volunteer bioequivalence support dosing. IKT-001 is in the global adaptive Phase 3 IMPROVE-PAH trial. Founded in 2008, headquartered in Wilmington, Delaware.